Objective To explore the predictive value of IGF⁃1 for ovarian response and ooctye quality in Mid⁃luteal phase GnRHa protocol. Methods Serum at the day of starting Gn therapy（Gn starting Day）and the day of HCG use（Day HCG）were collected from patients in our center taking Mid ⁃luteal phase GnRHa protocol and following Donor ⁃sperm IVF（D ⁃ IVF）. And then analyzing the relationship of IGF ⁃1 and clinical outcomes. Results There was no difference of IGF⁃1 in Gn starting Day in high response and normal response Groups. IGF⁃1 in Gn starting Day was significant higher in clinical pregnant group than in nonpregnant group. IGF⁃1 in Gn starting Day was an important factor affecting clinical outcome（OR = 0.987，95%CI：0.977 ~ 0.998，P = 0.021）. Receiver operator curve（ROC）for IGF⁃1 in Gn starting Day to predict clinical outcome of one transfer cycle showed that area under the curve（AUC）was 0.669（P = 0.029）. Conclusions When taking Mid⁃luteal phase GnRHa protocol， IGF⁃1 in Gn Starting Day cannot predict ovarian response but has predictive values for clinical pregnancy.